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Abstract
The world is immersed in “big data”. Big data has brought about radical innovations in the methods used to capture,
transfer, store and analyze the vast quantities of data generated every minute of every day. At the same time; however,
it has also become far easier and relatively inexpensive to do so. Rapidly transforming, integrating and applying this
large volume and variety of data are what underlie the future of big data. The application of big data and predictive
analytics in healthcare holds great promise to drive innovation, reduce cost and improve patient outcomes, health
services operations and value. Acute kidney injury (AKI) may be an ideal syndrome from which various dimensions and
applications built within the context of big data may influence the structure of services delivery, care processes and
outcomes for patients. The use of innovative forms of “information technology” was originally identified by the Acute
Dialysis Quality Initiative (ADQI) in 2002 as a core concept in need of attention to improve the care and outcomes for
patients with AKI. For this 15th ADQI consensus meeting held on September 6–8, 2015 in Banff, Canada, five topics
focused on AKI and acute renal replacement therapy were developed where extensive applications for use of big data
were recognized and/or foreseen. In this series of articles in the Canadian Journal of Kidney Health and Disease, we
describe the output from these discussions.
ABRÉGÉ
Le monde nage actuellement dans une mer de données informatiques. L’apparition de mégadonnées a entraîné des
changements majeurs dans la façon de saisir, de transférer, de stocker et d’analyser la multitude de données générée
chaque minute de chaque jour. Parallèlement, il est aussi plus facile de gérer ces informations et de le faire à un coût
relativement moindre. La capacité de transformer, d’intégrer et d’appliquer rapidement la variété et le volume
considérable de données est ce sur quoi repose le futur des mégadonnées. Le traitement des mégadonnées ainsi que
leur analyse prévisionnelle dans le système de santé se veut très prometteur pour favoriser l’innovation, réduire les
coûts, apporter des changements favorables au fonctionnement et à la portée des services ainsi que pour améliorer le
pronostic des patients. Il semble que l’insuffisance rénale aiguë (IRA) soit un syndrome idéal à partir duquel les
différents aspects et applications mis en place pour gérer les mégadonnées pourraient influencer les modèles existants
de prestation de services et d’offre de soins et, par extension, l’évolution de l’état de santé des patients. L’utilisation de
formes novatrices pour assimiler les technologies et l’information a d’abord été identifiée en 2002 par l’Acute Dialysis
Quality Initiative (ADQI) en tant que concept nécessitant une attention particulière et qui pourrait améliorer les soins et
le pronostic des patients atteints d’IRA. Lors de la 15e réunion annuelle de concertation de l’ADQI qui s’est tenue du 6
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au 8 septembre 2015 à Banff, au Canada, on a mis l’accent sur cinq thèmes reliés à l’IRA et aux thérapies de
remplacement rénal. Ils ont été développés dans des cadres où l’on reconnaissait ou prévoyait l’application étendue
des mégadonnées. Dans une série d’articles qui paraîtra dans le Canadian Journal of Kidney Health and Disease, nous
ferons ressortir les conclusions de ces discussions.
Introduction
“In God we trust; all others must bring data.” – W.
Edwards Deming
We are immersed in a world characterized by “Big
Data” [1] The term big data was likely first used in 1997
to describe the mounting challenges for computing
systems to manage immense data sets [2]. Indeed, ac-
cording to Wikipedia, big data is “a broad term for data
sets so large or complex that traditional data processing
applications are inadequate” [3]. This has necessitated
radical innovation in the methods used to capture, trans-
fer, store and analyze the utterly incomprehensible
volumes of data generated in society every minute of
every day. Yet, at the same time, it has become relatively
easy and inexpensive to do so. Technological innova-
tions have enabled many of our day-to-day activities to
be “data-fied” and leave unique and discrete digital
traces, from personal (i.e., web searching, wearing a
smart watch) to professional tasks (i.e., use of electronic
clinical information systems or medical records). Indeed,
nearly all forms of new technology introduced today
have integrated computers and sensors. Our capacity to
integrate this large volume and variety of data, relatively
quickly (three of the four characteristic “V”s of big data:
volume, velocity, variety and veracity) are what underlies
the future and promise of big data. Its potential has
brought about a revolution of changes in the fields of
science (i.e., genomics, meteorology, astrophysics), busi-
ness (i.e., retail, banking), and media and communica-
tions (i.e., data exhaust, and mouse clicks on Facebook,
Amazon, and Google).
Big data in healthcare
The use of big data and predictive analytics in healthcare
also holds great promise to drive innovation, increase
efficiency, improve outcomes for patients and reduce costs
while advancing the value of service delivery [4]. Big data in
healthcare aims to introduce new technologies to acquire,
integrate and analyze data to guide clinical research,
optimize hospital operations and inform “best” clinical
practice [5]. However, “data” is not synonymous with
information or for that matter with knowledge. Big data
has challenges. The sheer quantity of data is growing faster
than our capacity to aptly utilize and apply it. Similarly, it
remains uncertain whether unconventional sources and
unstructured data, clearly a departure from classical epi-
demiological teaching, can be appropriately and/or suitably
applied to inform about health and disease. Examples
include the use of social media to estimate obesity preva-
lence or Google Flu to trend influenza rates [6, 7]. Chunara
et al estimated population obesity rates by performing a
cross-sectional study correlating described user interests on
the social network Facebook in New York City neighbor-
hoods with national obesity prevalence rates. In this study,
a greater proportion of user activity-interests in television
correlated with a higher prevalence of obesity [6]. Alterna-
tively, during the 2013 influenza season, Google Flu Trends
(GFT) grossly over-estimated the incidence of influenza
compared with Centers for Disease Control (CDC) surveil-
lance reports, attributed largely to modifications and imper-
fections in the GFT search algorithm [7].
The practice of medicine has traditionally relied on the
skills of clinicians, which to a great extent relies on “clinical
intuition”. In acute care settings, clinicians commonly size
up a clinical situation by, often subconsciously, integrating
multi-modal sources of data from history, physical examin-
ation, diagnostic imaging and laboratory investigations,
along with temporal visual cues, to inform their actions.
The complexity of big data at the bedside is rapidly grow-
ing, and while still modest, the volume (along with velocity,
variety and veracity) can greatly exceed that which clini-
cians can conceivably integrate and consciously analyze into
their clinical decision making. Naturally then, experienced
clinicians use a variety of heuristics to guide their clinical
assessment and bedside decision-making. Part of the appeal
of big data is the potential for computers and capacity for
complex analytics to reproduce (and improve on) these
clinical heuristics to better inform patient care, along with
improve healthcare system operations. Finally, issues related
to privacy, security and ownership of data have understand-
ably emerged to worry patients, providers and custodians
of health data. These challenges aside, big data will certainly
continue to influence the nature of healthcare, if not
reshape and define it, in terms of prognostics, surveillance,
operations and service delivery, across a broad continuum
for the foreseeable future.
How then can big data apply to acute kidney
injury (AKI)?
We contend that AKI may be an ideal syndrome to use
big data to develop applications to guide and influence
the structure of services delivery, care processes and
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outcomes for patients [8]. The use of innovative forms
of “information technology” was originally identified by
the Acute Dialysis Quality Initiative (ADQI) in 2002 as a
core concept in need of attention to improve the care
and outcomes for patients with AKI [9].
Indeed, AKI may be an important syndrome to focus on
for a variety of reasons [10]. First, AKI is common in hospi-
talized patients [11]. Second, AKI imposes a significant
increased risk for major morbidity, including chronic kid-
ney disease and accelerated progression to end-stage kidney
disease and death [12, 13]. Third, AKI is expensive [14, 15].
Patients suffering an episode of AKI consume greater re-
sources and incur higher costs, largely from intensified
monitoring, investigations, and support and longer hospital
stays. Finally, and perhaps most importantly, recent data
highlight how the care of patients with AKI is suboptimal,
even poor, and characterized by numerous deficiencies and
systematic failings, implying much may in fact be avoidable
[16, 17]. Accordingly, based on these assertions, we believed
that an ADQI consensus meeting focused on how big data
could transform and/or translate into tangible improve-
ment in AKI care was justified and needed.
AKI in the era of big data
For this ADQI consensus meeting, we proposed five
discrete yet overlapping topics within the broad realm of
critical care nephrology, specifically focused on AKI and
RRT, whereby we recognized and/or foresaw extensive
applications for use of big data. The first topic focused
the concept of development and utilization of predictive
analytics, forecasting and risk identification applications
for AKI, leveraged on the existing and/or planned inte-
gration of electronic medical records (EMR) and clinical
information systems (CIS) available at the point of care.
Conceptually, this would enable a hospital-wide platform
for clinical risk prediction and integration decision sup-
port to mitigate “avoidable” episodes of AKI [18]. The
second topic focused on particular methodology to de-
velop novel applications to detect and classify AKI among
hospitalized patients using EMR/CIS platforms. Concep-
tually, this would enable the detection of AKI at the earli-
est opportunity and provide maximal lead time to mitigate
avoidable propagation of AKI or harm [19–21]. The third
topic focused on the concept of automated electronic
alerting for patients either at-risk or who have had overt
AKI detected. This topic focused on the methods and
forms of communicating alerts regarding AKI to inter-
disciplinary providers along with the integration, context
and format of decision support [22–24]. The fourth topic
aimed to revisit how AKI is currently “coded” across ad-
ministrative databases [25–27]. This topic also focused on
how existing administrative, clinical and research database
infrastructure may be leveraged for “risk identification” for
large scale pragmatic registry-based clinical trials or used
for quality assurance, outcome, health system utilization
focused projects [28, 29]. The final topic aimed to estab-
lish how big data could trace the arc of care for a patient
who suffered an episode of AKI associated with a discrete
hospitalization by optimally utilizing a wide variety of data
sources [30]. Conceptually, this may represent the critical
pathway of a patient as they transition through various
aspects of a health system that can inform on the “natural”
history of AKI.
In this series of articles in the Canadian Journal of
Kidney Health and Disease, we aim to describe the out-
put from our discussions that took place during the 15th
ADQI consensus conference on “Acute Kidney Injury in
the Era of Big Data” in Banff, Canada on September 6–8,
2015.
ADQI methodology
The methodology of ADQI consensus conferences are
well developed and have been further refined over the
last decade, as previously described [31, 32]. In brief, the
ADQI methodology begins with a systematic search and
appraisal of scientific evidence to identify emerging
priorities in the field. This is followed by a surveillance
of current practice, evidence implementation and/or
integration of evidenced-based techniques, along with
identification of key areas where knowledge or care gaps
are prevalent.
For the 15th ADQI consensus conference, the meeting
chairs selected the broad theme of “Acute Kidney Injury in
the Era of Big Data” to acknowledge the evolving nature
and growing importance of information and technology in
the care of patients with AKI. The meeting chairs invited
a diverse expert panel representing relevant disciplines
(i.e., nephrology, critical care, pediatrics, pharmacy, epi-
demiology, biostatistics, and informatics) from a variety of
countries and scientific societies around this theme. The
methodology utilized a process of both “evidence ap-
praisal” and “expert panel” [33].
The activities of the ADQI consensus conferences have
been traditionally partitioned into three discrete phases:
pre-conference, conference and post-conference. In the
preconference phase, key topics for each work group are
developed and refined, work groups are established (4–6
members per group), and specific topics are assigned.
Each work group developed a series of key questions
focused on their topic, performed a systematic review of
the literature, and summarized the current state of
knowledge to facilitate further refinement of their key
questions from which discussion and consensus state-
ments could be developed.
The conference phase is characterized by a series of
breakout sessions where each work group aims to iden-
tify key issues, grade the evidence, classify the current
state of consensus and develop summary statements and
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where applicable, provide recommendations. These ses-
sions alternate with plenary sessions, where each work
group iteratively presents their questions addressing each
identified issue along with draft consensus statements.
Throughout this process, each question and statement are
discussed, debated, and further refined as necessary. This
process also aims to facilitate translation of identified
knowledge gaps into future agendas for research. The con-
ference chairs act as facilitators during both the breakout
and plenary sessions.
During the post-conference phase, each work group
consolidates their findings, specifically their background,
rationale and evidence synthesis with their key questions
and consensus statements in a concise manuscript. Each
manuscript is circulated among work groups for comment
and further edited for style and uniformity by the confer-
ence chairs.
The broad objectives of ADQI are to provide expert-
based statements and interpretation of current knowledge
for use by clinicians according to professional judgment
and identify evidence care gaps to facilitate research prior-
ities. For the 15th ADQI consensus conference, the focus
was on the rapid emergence of big data in healthcare and
how it may impact the field of critical care nephrology.
We believe that the five papers presented in this series in
the Canadian Journal of Kidney Health and Disease will
provide a broad overview of the current status of big data
in AKI and a roadmap for its future applications to
improve care delivery and outcomes for patients.
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